ReconTop Stories

JOURNEY™ II BCS Knee System demonstrates improved patient outcomes and lower healthcare costs

LONDONJuly 25, 2018 /PRNewswire/ — Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced positive clinical results concerning its JOURNEY™ II Bi-Cruciate Stabilized (BCS) knees. These results suggest JOURNEY II BCS is associated with significant healthcare economic benefits in patients implanted with this device compared to other knee systems.

In a retrospective cohort study from the Premier Perspective Database1, JOURNEY II BCS patients exhibited lower mean hospital stays and overall reduced mean costs when compared to other knee patients.  When comparing 1,692 JOURNEY II BCS patients to the same number of other comparable knee patients, data revealed JOURNEY II BCS patients were:

  • 51% less likely to be readmitted to the hospital within 30 days;
  • 35% more likely to be discharged to their home; and
  • 41% less likely to be discharged to a skilled nursing facility for further care.

The results also showed patients with JOURNEY II BCS experienced statistically significantly reduced length of stay and reduced hospital costs, equivalent to approximately 10% in savings to the overall procedure cost ($16,187 vs. $17,877).

Andy Weymann MD, Chief Medical Officer of Smith & Nephew, commented: “To have a knee system that improves patient outcomes while reducing healthcare costs is a tremendous feat for Smith & Nephew.  When we introduced the JOURNEY II Knee System, we wanted to build upon our 150+ years of supporting healthcare professionals and patients in a way that addressed the market where patient outcome measures go beyond implant survivorship.  We know hospitals and healthcare professionals have a wide choice in knee implants and this new retrospective analysis supports our view that JOURNEY II BCS is the leading knee platform available in today’s market.”

The Premier Perspective Database study is not the only recent evidence reporting improved patient outcomes with the JOURNEY II BCS Knee System. In another multi-center study published in Techniques in Orthopaedics, JOURNEY II BCS patients demonstrated a smoother recovery, improved function and increased patient satisfaction.2-6 Specifically, study patients implanted with JOURNEY II BCS had 23 degrees more flexion than patients implanted with another comparable knee system along with significantly improved mean knee society scores (89 vs 81; p<0.001) at 1 year follow-up.2

“Every knee product we manufacture is designed to improve patient outcomes while decreasing hospital costs. It is rewarding to see JOURNEY II BCS patients demonstrating a smoother recovery1-2 and higher patient satisfaction than what we have seen in the past. These outcomes illustrate the value that Smith & Nephew constantly strives to provide to our healthcare system,” Brad Cannon, Chief Marketing Officer.

The JOURNEY II BCS is a member of the JOURNEY II Total Knee Arthroplasty (TKA) system, which also includes JOURNEY II Cruciate Retaining (CR) and the recently launched bi-cruciate retaining JOURNEY II XR.

About Smith & Nephew 

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on

Forward-looking Statements 

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include:

economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

  1. Mayman DJ, Patel AR, Carroll KM. Hospital Related Clinical and Economic Outcomes of a Bicruciate Knee System in Total Knee Arthroplasty Patients.Poster presented at: ISPOR Symposium; May 19-23, 2018Baltimore, Maryland, USA.
  2. Nodzo, SR; Carroll KM, Mayman DJ. The Bicruciate Substituting Knee Design and Initial Experience. Tech Orthop. 2018;33:37-41.
  3. Scott CE, Howie CR, MacDonald D, Biant LC; Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients. J Bone Joint Surg Br. 2010 Sep;92(9)
  4. J Orthop. 2017 Jan 7;14(1):201-206. doi: 10.1016/j.jor.2016.12.005. eCollection 2017. Bi-cruciate substituting total knee arthroplasty improved medio-lateral instability in mid-flexion range
  5. In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy Trevor F. Grieco, MS a, *, Adrija Sharma, PhD a, Garett M. Dessinger, BS a, Harold E. Cates, MD b, Richard D. Komistek, PhD. The Journal of Arthroplasty, September 2017
  6. A comparison of Rolback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty. DOI: 10.1055/s-0037-1604445. ISSN 1538-8506. The Journal of Knee Surgery. Takanori Iriuchishima, Keinosuke Ryu

SOURCE Smith & Nephew

Related Links


Drue is Managing Partner for The De Angelis Group.

Related Articles

Back to top button